Zynex, Inc. announces an Equity Buyback for $20 million worth of its shares.
February 01, 2024 at 02:45 am IST
Share
Zynex, Inc. (NasdaqGS:ZYXI) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will be funded from the company's existing cash balances.
The program will expire on the earlier of March 4, 2025, or the date on which the company repurchases the maximum amount authorized under the program. As of October 30, 2023, the company had 42,000,000 million shares issued and 32,200,000 shares outstanding.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.